Serina Therapeutics: files certificate eliminating Series A preferred stock

What happened Serina Therapeutics filed a Certificate of Elimination with the Secretary of State of the State of Delaware on Oct 5, 2026, eliminating from the company’s certificate of incorporation all matters set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock. The filing states that none of the shares of Series A Preferred Stock are outstanding because all issued and outstanding shares were converted into shares of the company’s common stock, and that upon filing the shares resumed the status of authorized but unissued preferred stock without designation as to series.

Key details

• Certificate of Elimination filed Oct 5, 2026 pursuant to Section 151(g) of the Delaware General Corporation Law.
• Series A Convertible Preferred Stock, par value $0.0001 per share.
• Certificate of Designations for the Series A Preferred Stock was originally filed Apr 10, 2025 and corrected May 22, 2025.
• The filing states all issued and outstanding Series A shares have been converted into common stock; none remain outstanding.

Why it may matter This report is filed under Item 5.03 (amendments to articles of incorporation or bylaws) and covers a change to the company’s charter removing the Series A designations. A filing does not show why the insider traded or why the company acted.